Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Iovance Biotherapeutics, Inc.
  6. Summary
    IOVA   US4622601007

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
11.57 USD   +0.87%
07/01Goldman Sachs Adjusts Iovance Biotherapeutics' Price Target to $18 From $64, Maintains Buy Rating
MT
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQGM : IOVA) added to Russell 2000 Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQGM : IOVA) added to Russell 2000 Value Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
10.98(c) 10.89(c) 11.04(c) 11.47(c) 11.57(c) Last
5 130 356 3 450 186 3 322 135 4 141 693 4 493 235 Volume
-1.35% -0.82% +1.38% +3.89% +0.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -393 M - -
Net cash position 2022 222 M - -
P/E ratio 2022 -4,71x
Yield 2022 -
Sales 2023 65,3 M - -
Net income 2023 -374 M - -
Net cash position 2023 165 M - -
P/E ratio 2023 -5,20x
Yield 2023 -
Capitalization 1 818 M 1 818 M -
EV / Sales 2022 -
EV / Sales 2023 25,3x
Nbr of Employees 319
Free-Float 91,8%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which... 
Read more
More about the company
Ratings of Iovance Biotherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
07/01Goldman Sachs Adjusts Iovance Biotherapeutics' Price Target to $18 From $64, Maintains ..
MT
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) added to Russell 2000 Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) added to Russell 2000 Value Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Dynamic Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 3000 Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Value Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) added to Russell 2000 Dynamic Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Midcap Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Small Cap Comp Growth In..
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 3000E Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Midcap Value Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Midcap Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 2500 Growth Index
CI
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
06/13Iovance Biotherapeutics, Inc. nomme Wendy L. Dixon au conseil d'administration
06/03Iovance Biotherapeutics augmente vendredi après-midi après l'achat d'actions de la soci..
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé terminent en hausse
05/27Les actions d'Iovance Biotherapeutics chutent après les résultats d'un essai clinique s..
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé progressent vendredi avant le..
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 11,57 $
Average target price 27,23 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Frederick G. Vogt President, CEO, Secretary & General Counsel
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Kristin Lanzi Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
IOVANCE BIOTHERAPEUTICS, INC.-39.92%1 803
EXACT SCIENCES CORPORATION-47.15%7 237
BGI GENOMICS CO., LTD.-18.99%4 461
GUARDANT HEALTH, INC.-56.35%4 450
BEIJING STRONG BIOTECHNOLOGIES, INC.-7.97%1 588
VERACYTE, INC.-48.79%1 507